Upstream Bio Corp (UPB) - Business Payback Period
Upstream Bio Inc (UPB) is in the early stages of developing immunological agents, meaning its financial stability depends on external funding. The company's normalized P/E, as shown on this GURU.Markets chart, indicates that the current parameter is -1.30. The asset's price action depends on the safety of verekimab and FDA approval, while the overall strategy relies on the validation of molecules to combat severe inflammation.
Analytical breakdowns for Upstream Bio Inc
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
Total Debt to Capital Upstream Bio Inc|UPB - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Upstream Pharma|UPB - Company Aggregate Debts|Debts to Book Value Upstream Bio Inc|UPB - Company Long-Term Liabilities|Company Short-Term Debts Upstream Bio|Critical Liquidity Ratio upstreambio.com
- company profitability and valuation multiples indicators:
UPB - Company Net Income|Company Profit Forecast Upstream Bio Inc|UPB - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Upstream Bio, Inc.|UPB - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Upstream Bio Inc|UPB - Operating profit EBITDA|Net earnings per one share for the last twelve months Upstream Bio|UPB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth upstreambio.com|UPB - Earnings per share growth in current year|Expected earnings per share growth for next year Upstream Bio Inc
Summary company analysis:UPB (upstreambio.com)
The P/E ratio determines the cost of a single unit of net profit, allowing an investor to assess the investment payback period and the extent of overpayment for an asset. When analyzing the current price-to-earnings valuation for the biotech startup Upstream Bio Inc (UPB), it is essential to consider the clinical development stage, where the absence of in-house production turns this metric into an indicator of market expectations for future drugs, confirming the asset's speculative resilience.
Competing companies
ARGX: Company Value to Net Income|P/E Multiple BNTX|Business Payback Period ABIVAX|Price to Earnings Ratio ADMA Bio ADMA|PTGX - Price to Earnings Ratio|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|GRFS (Grifols) - Price to Earnings Ratio|Adaptive Biotech (ADPT) - P/E Multiple|Price to Earnings Ratio Celldex|Price to Earnings Multiple AUPH (Aurinia Corp)|P/E Multiple BCRX|VERA - Market Cap to Earnings|Dianthus Therapeutics, Inc. - Price to Earnings Ratio|P/E Multiple Pharvaris NV PHVS|ABCL - Price to Earnings Ratio|Market Cap to Net Income TRML|Precigen, Inc. (PGEN) - Price to Earnings Ratio|PHAR - Business Payback Period|Price to Earnings Ratio NKTR|ZBIO (Zenas Bio) - Market Price to Net Income Ratio|Price to Earnings Ratio Immunome Corp (IMNM)|GOSS (Gossamer Bio Corp.) - Company Value to Net Income|P/E Multiple KALV (KalVista Pharmaceuticals)|septerna.com (SEPN) - Market Cap to Earnings|Pieris Pharmaceuticals, Inc. - P/E Multiple|SVRA - P/E Multiple|Rigel Pharmaceuticals Inc (RIGL) - Price to Earnings Ratio|Price to Earnings Ratio AnaptysBio Inc.|Price to Earnings Ratio ATXS|ENGN: Company Value to Net Income|P/E Multiple RAPT|Price to Earnings Ratio JBIO (aerovatetx.com)|P/E Multiple ACRS (Aclaris)|Business Payback Period Kyverna Therapeutics, Inc (KYTX)|TLSA - Price to Earnings Ratio|Market Cap to Earnings cabalettabio.com|VTYX (Ventyx Biosciences, Inc.) - Price to Earnings Ratio|Theratechnologies, Inc. - Company Value to Net Income|AVTX (Avalo Therapeutics Inc.) - P/E Multiple|Eledon Pharmaceuticals, Inc (ELDN) - Business Payback Period|Price to Earnings Ratio Agenus (AGEN)|climbbio.com - Price to Earnings Multiple|P/E Multiple ZURA (Zura Bio)|ATYR - Price to Earnings Ratio|ADAG: Price to Earnings Ratio|IMA - P/E Multiple|shattucklabs.com (STTK) - Price to Earnings Ratio|Market Cap to Net Income EQ (Equillium)|CNTB (Connect Biopharma Holdings) - P/E Multiple|Price to Earnings Ratio IMUX|Price to Earnings Ratio Atara Biotherapeutics (ATRA)|IFRX: Market Cap to Net Income|P/E Multiple XFOR (X4 Pharmaceuticals)|Company Value to Net Income ACET|Celularity Corp - P/E Multiple|INMB - P/E Multiple|Barinthus Bio (BRNS) - Price to Earnings Ratio|Kezar Life Sciences Inc - Company Value to Net Income|Price to Earnings Ratio SAB Biotherapeutics|Price to Earnings Ratio akaritx.com (AKTX)|P/E Multiple ENLV|P/E Multiple q32bio.com (QTTB)|GeoVax Labs Inc - Price to Earnings Ratio|Company Value to Net Income EDSA|iBio, Inc. - P/E Multiple|Business Payback Period Carisma Therapeutics CARM|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Price to Earnings Ratio Bolt Biotherapeutics, Inc.|Price to Earnings Ratio HCW Biologics, Inc.|Price to Earnings Ratio Aptevo (APVO)|Price to Earnings Ratio AIM (AIM ImmunoTech Inc.)|P/E Multiple aditxt.com (ADTX)|Price to Earnings Ratio GRI Bio GRI|XRTX: Price to Earnings Multiple|ReShape Lifesciences - P/E Multiple|Market Cap to Earnings Revelation Biosciences Corp|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|scinai.com (SCNI) - P/E Multiple|Price to Earnings Ratio CalciMedica Inc|Affimed Therapeutics - Market Cap to Net Income|Price to Earnings Ratio Allakos Inc. (ALLK)|Business Payback Period hookipapharma.com|IGM Biosciences - Price to Earnings Ratio|Market Price to Net Income Ratio ITOS (iteostherapeutics.com)|OCEA - Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) Plc)|THRD: P/E Multiple
